Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis

References

• AkrichM.1992. “The De-Scription of Technical Objects.” In Shaping Technology–Building Society: Studies in Sociotechnical Change, edited by W. E.Bijker and J.Law, 205–224. Cambridge, MA: MIT Press.
   Google Scholar
• ArnoldE. A., P.Hazelton, T.Lane, K. A.Christopoulos, G. R.Galindo, W. T.Steward, and S. F.Morin. 2012. “A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV Infection.” PLoS ONE7 (7)
   Web of Science ®Google Scholar
• BaetenJ., and R.Grant. 2013. “Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?” Current HIV/AIDS Reports10 (2): 142–151.
   PubMedGoogle Scholar
• BrooksR. A., R. J.Landovitz, R. L.Kaplan, E.Lieber, S.-J.Lee, and T. W.Barkley. 2012. “Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis among HIV-negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study.” AIDS Patient Care and STDs26 (2): 87–94.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2011. “Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men.” Morbidity and Mortality Weekly Report60 (3): 65–68.
   PubMedGoogle Scholar
• DavisM.2002. “HIV Prevention Rationalities and Serostatus in the Risk Narratives of Gay Men.” Sexualities5 (3): 281–299.
   Google Scholar
• GilmoreH. J., A.Liu, K. A.Koester, K. R.Amico, V.McMahan, P.Goicochea, L.Vargas, D.Lubensky, S.Buchbinder, and R.Grant. 2013. “Participant Experiences and Facilitators and Barriers to Pill Use among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco.” AIDS Patient Care and STDs27 (10): 560–566.
   PubMed Web of Science ®Google Scholar
• GrantR. M., J. R.Lama, P. L.Anderson, V.McMahan, A. Y.Liu, L.Vargas, P.Goicochea, et al. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.” New England Journal of Medicine363 (27): 2587–2599.
   PubMed Web of Science ®Google Scholar
• HoltM.2014. “HIV Pre-Exposure Prophylaxis and Treatment as Prevention: A Review of Awareness and Acceptability among Men Who Have Sex with Men in the Asia-Pacific Region and the Americas.” Sexual Health11 (2): 166–170.
   PubMed Web of Science ®Google Scholar
• JensenT. E.2012. “Intervention by Invitation: New Concerns and New Versions of the User in STS.” Science Studies25 (1): 13–36.
   Google Scholar
• KarrisM. Y., S. E.Beekmann, S. R.Mehta, C. M.Anderson, and P. M.Polgreen. 2014. “Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada.” Clinical Infectious Diseases58 (5): 704–712.
   PubMed Web of Science ®Google Scholar
• KirbyT., and M.Thornber-Dunwell. 2014. “Uptake of PrEP for HIV Slow among MSM.” The Lancet383 (9915): 399–400.
   PubMed Web of Science ®Google Scholar
• KrakowerD., N.Ware, J. A.Mitty, K.Maloney, and K. H.Mayer. 2014. “HIV Providers' Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study.” AIDS & Behavior18 (9): 1712–1721.
   PubMed Web of Science ®Google Scholar
• LandowitzR. J.2012. “How PrEP Will Roll Out in Practice (Slowly, So Far).” Research Initiative Treatment Action!17 (2): 34–40.
   Google Scholar
• LatourB.2005. Reassembling the Social: An Introduction to Actor Network Theory. Oxford: Clarendon.
   Google Scholar
• LiuA., S.Cohen, S.Follansbee, D.Cohan, S.Weber, D.Sachdev, and S.Buchbinder. 2014. “Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco.” PLoS Medicine11 (3): e1001613.
   PubMed Web of Science ®Google Scholar
• McNeilD. G.2014. “Advocating Pill, U.S. Signals Shift to Prevent AIDS.” New York Times. http://nyti.ms/1jh5UbJ.
   Google Scholar
• MimiagaM. J., E. F.Closson, V.Kothary, and J. A.Mitty. 2014. “Sexual Partnerships and Considerations for HIV Antiretroviral Pre-Exposure Prophylaxis Utilization among High-Risk Substance Using Men Who Have Sex with Men.” Archives of Sexual Behavior43 (1): 99–106.
   PubMed Web of Science ®Google Scholar
• MontgomeryC. M.2012. “Making Prevention Public: The Co-Production of Gender and Technology in HIV Prevention Research.” Social Studies of Science42 (6): 922–944.
   Web of Science ®Google Scholar
• MorinS. F., G.Yamey, and G. W.Rutherford. 2012. “HIV Pre-Exposure Prophylaxis.” BMJ345 (August 13): e5412.
   PubMed Web of Science ®Google Scholar
• OudshoornN., and T.Pinch. 2003. “User-Technology Relationships: Some Recent Developments.” In How Users Matter: The Co-Construction of Users and Technologies, edited by N.Oudshoorn and T.Pinch, 541–565. Cambridge, MA: MIT Press.
   Google Scholar
• PaxtonL. A., T.Hope, and H. W.Jaffe. 2007. “Pre-Exposure Prophylaxis for HIV Infection: What If It Works?” The Lancet370 (9581): 89–93.
   PubMed Web of Science ®Google Scholar
• PerssonA.2013. “Notes on the Concepts of ‘Serodiscordance’ and ‘Risk’ in Couples with Mixed HIV Status.” Global Public Health8 (2): 209–220.
   PubMed Web of Science ®Google Scholar
• PottsA.2005. “Cyborg Masculinity in the Viagra Era.” Sexualities, Evolution & Gender7 (1): 3–16.
   Google Scholar
• PoundP., N.Britten, M.Morgan, L.Yardley, C.Pope, G.Daker-White, and R.Campbell. 2005. “Resisting Medicines: A Synthesis of Qualitative Studies of Medicine Taking.” Social Science & Medicine61 (1): 133–155.
   PubMed Web of Science ®Google Scholar
• RaceK.2003. “Revaluation of Risk among Gay Men.” AIDS Education and Prevention15 (4): 369–381.
   PubMed Web of Science ®Google Scholar
• RosengartenM., and M.Michael. 2010. “HIV Pre-Exposure Prophylaxis (PrEP) and the Complexities of Biomedical Prevention: Ontological Openness and the Prevention Assemblage.” In HIV Treatment and Prevention Technologies in International Perspective, edited by M.Davis and C.Squire, 167–183. Basingstoke: Palgrave Macmillan.
   Google Scholar
• SaberiP., K. E.Gamarel, T. B.Neilands, M.Comfort, N.Sheon, L. A.Darbes, and M. O.Johnson. 2012. “Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-Exposure Prophylaxis among Male Couples in San Francisco: A Mixed Methods Study.” PLoS ONE7 (11): e50061.
   PubMed Web of Science ®Google Scholar
• StadlerJ., and E.Saethre. 2011. “Blockage and Flow: Intimate Experiences of Condoms and Microbicides in a South African Clinical Trial.” Culture, Health & Sexuality13 (1): 31–44.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 2012. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection. Silver Spring, New Hampshire: US Department of Health & Human Services.
   Google Scholar
• WoolgarS.1991. “Configuring the User: The Case of Usability Trials.” In A Sociology of Monsters: Essays on Power, Technology and Domination, edited by J.Law, 58–99. London: Routledge.
   Google Scholar
• YouleM., and M. A.Wainberg. 2003. “Pre-Exposure Chemoprophylaxis (PrEP) as an HIV Prevention Strategy.” Journal of the International Association of Physicians in AIDS Care (JIAPAC)2 (3): 102–105.
   PubMedGoogle Scholar
• YoungI., and L.McDaid. 2014. “How Acceptable are Antiretrovirals for the Prevention of Sexually Transmitted HIV?: A Review of Research on the Acceptability of Oral Pre-exposure Prophylaxis and Treatment as Prevention.” AIDS & Behavior18 (2): 195–216.
   PubMed Web of Science ®Google Scholar